How Does Opdivo Work Against Cancer?
Opdivo (nivolumab) is a monoclonal antibody that blocks the programmed death-1 (PD-1) receptor on T cells. PD-1 is an immune checkpoint protein that cancer cells exploit by expressing PD-L1 ligands, which bind to PD-1 and inhibit T-cell activation, allowing tumors to evade immune detection. By binding PD-1 with high affinity, Opdivo prevents this interaction, reactivating T cells to recognize and attack cancer cells.[1][2]
What Cancers Is Opdivo Approved For?
The FDA has approved Opdivo for over a dozen cancers, including melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer (MSI-H/dMMR), hepatocellular carcinoma, esophageal cancer, gastric cancer, and others, often in combination with drugs like ipilimumab or chemotherapy.[1][3]
How Does Opdivo Compare to Similar Drugs Like Keytruda?
Opdivo and Keytruda (pembrolizumab) both target PD-1 but differ slightly in structure and binding—Opdivo is a fully human IgG4 antibody, while Keytruda is a humanized IgG4. Clinical trials show comparable efficacy in many indications, though head-to-head data is limited; for example, in melanoma, Opdivo plus ipilimumab improved survival over either alone, similar to Keytruda combos. Choice often depends on trial data for specific cancers and patient PD-L1 expression.[2][4]
What Are Common Side Effects and Immune-Related Risks?
Opdivo boosts immune activity, leading to side effects like fatigue, rash, itching, diarrhea, nausea, and musculoskeletal pain. Serious immune-related adverse events occur in up to 20-30% of patients, including pneumonitis, colitis, hepatitis, endocrinopathies (e.g., thyroiditis), and rarely myocarditis or neurological issues. These require prompt corticosteroid management and can be fatal if untreated.[1][3]
Who Makes Opdivo and What's Its Patent Status?
Bristol Myers Squibb (BMS) manufactures and markets Opdivo. Key U.S. patents cover the PD-1 antibody composition and methods of use, with core patents expiring around 2028-2032, though extensions and litigation (e.g., against Samsung Bioepis biosimilar) could delay generics. Check DrugPatentWatch.com for latest expiry dates and challenges.[5]
[1]: FDA Label for Opdivo (nivolumab), https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125554s302lbl.pdf
[2]: Brahmer JR et al., "Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer," N Engl J Med, 2015
[3]: NCCN Guidelines, various cancers, 2023
[4]: Robert C et al., "Nivolumab in previously untreated melanoma without BRAF mutation," N Engl J Med, 2015
[5]: DrugPatentWatch.com, Opdivo patents, https://www.drugpatentwatch.com/p/tradename/OPDIVO